Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2022 SS
-
2021 WS
-
2021 SS
-
2020 WS
-
2020 SS
-
2019 WS
-
2019 SS
-
2018 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized TrialIn: Clinical Cancer Research Jg. 29 (2023) Nr. 17, S. 3313 - 3319Online Volltext: dx.doi.org/ (Open Access)
-
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-upIn: JAMA Oncology Jg. 6 (2020) Nr. 8, S. 1241 - 1246Online Volltext: dx.doi.org/ (Open Access)
-
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP : results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trialIn: Annals of Hematology Jg. 98 (2019) Nr. 4, S. 897 - 907Online Volltext: dx.doi.org/
-
GFI1B-A novel oncosuppressor which restricts number of leukemic stem stellsIn: Haematologica / The Hematology Journal Jg. 102 (2017) Nr. Suppl. 2, S. 204 - 204
-
Growth factor independence 1 (GFI !) regulates the AML supporting function of mesenchymal stromal cellsIn: Haematologica / The Hematology Journal Jg. 102 (2017) Nr. Suppl. 2, S. 459 - 459
-
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence?In: The European Journal of Cancer Jg. 59 (2016) S. 128 - 133Online Volltext: dx.doi.org/ (Open Access)
-
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibIn: Cancer Jg. 120 (2014) Nr. 15, S. 2325 - 2333Online Volltext: dx.doi.org/ (Open Access)
-
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerIn: Breast Cancer Research and Treatment Jg. 134 (2012) Nr. 3, S. 1149 - 1159Online Volltext: dx.doi.org/ (Open Access)
-
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trialIn: JAMA: Journal of the American Medical Association Jg. 307 (2012) Nr. 12, S. 1265 - 1272Online Volltext: dx.doi.org/
-
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)In: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 30 (2012) Nr. 3, S. 1184 - 1192Online Volltext: dx.doi.org/
-
The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in miceIn: Blood Jg. 120 (2012) Nr. 19, S. 4006 - 4017Online Volltext: dx.doi.org/
-
First-line treatment of patients with metastatic pancreatic cancer : Results of a Phase II trial with S-1 (CESAR-Study group)In: International Journal of Clinical Pharmacology and Therapeutics Jg. 48 (2010) Nr. 7, S. 470 - 472Online Volltext: dx.doi.org/
-
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinibIn: International Journal of Cancer Jg. 117 (2005) Nr. 2, S. 316 - 325Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumorsIn: Journal of Nuclear Medicine Jg. 45 (2004) Nr. 3, S. 357 - 365
-
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KITIn: Cancer Chemotherapy and Pharmacology Jg. 51 (2003) Nr. 3, S. 261 - 265Online Volltext: dx.doi.org/
-
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST) : Survival analysis of a randomized trial after 10 years of follow-upIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 11503Online Volltext: dx.doi.org/
-
Curcumin as a treatment approach for MDS/AML in human
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 76Online Volltext: dx.doi.org/ (Open Access)